Anti-inflammatory explained
Anti-inflammatory refers to any drug, substance or mechanism that reduces inflammation by lessening the redness, swelling, fever, or pain and loss of function which are part of bodies inflammatory response. Anti-inflammatory drugs are agents that inhibit action or production of inflammatory mediators such as cytokines, histamines and prostaglandins. These drugs reduce pain by inhibiting mechanisms of inflammation, as opposed to opioids, which affect the central nervous system to block pain.[1]
Common anti-inflammatory drugs include nonsteroidal anti-inflammatory drugs (NSAIDs),[2] corticosteroids, antileukotrienes, and monoclonal antibodies.
Clinically approved
Nonsteroidal anti-inflammatory drugs
See main article: Nonsteroidal anti-inflammatory drug.
NSAIDs alleviate pain by counteracting the cyclooxygenase (COX) enzyme involved in pain mechanisms.[3]
Some common examples of NSAIDs are aspirin, ibuprofen, and naproxen.Selective COX-2 inhibitors, such as celecoxib, block the enzymatic conversion of arachidonic acid into prostaglandin, inhibiting inflammation and pain.[4]
Analgesics commonly associated with anti-inflammatory drugs, such as paracetamol (acetaminophen), have no peripheral anti-inflammatory effects.[5] High, short-term doses of NSAIDs may become toxic, causing gastric erosions, stomach ulcers, internal bleeding, hepatotoxicity, or kidney disease.
The risk of death as a result of GI bleeding caused by the use of NSAIDs is 1 in 12,000 for adults aged 16–45.[6] The risk increases almost twentyfold for those over 75. Apart from aspirin, frequent or high doses of prescription and over-the-counter NSAIDs may increase the risk of heart attack and stroke.[7]
Corticosteroids
Corticosteroids, specifically glucocorticoids or glucocorticoid receptor agonists, are powerful anti-inflammatory agents, but they are also powerful immunosuppressants and are associated with various toxicities, which constrain their use.[8] [9]
Antileukotrienes
Antileukotrienes are anti-inflammatory agents which function as leukotriene-related enzyme inhibitors (arachidonate 5-lipoxygenase) or leukotriene receptor antagonists (cysteinyl leukotriene receptors), and consequently oppose the function of these inflammatory mediators. Although they are not used for analgesic benefits, they are used to manage diseases related to inflammation of the lungs, such as asthma, as well as being used for sinus inflammation in allergic rhinitis.[10] [11] Examples include montelukast and zileuton.
Monoclonal antibodies
Monoclonal antibodies, for instance against pro-inflammatory cytokines like interleukin-6 (anti-interleukin-6) and tumor necrosis factor α (TNFα) (TNF inhibitors), are approved and used in the treatment autoimmune diseases and other inflammatory conditions.[12] [13] [14]
Colchicine
Colchicine is an anti-inflammatory agent that disrupts the function of cytoskeletal by inhibiting microtubule polymerization, doing so prevents the activation, degranulation and migration of neutrophils.[15] Colchicine is mostly used in treatment of acute gout. It can also be used for treating familial Mediterranean fever and pericarditis.[16]
Investigational and off-label
Omega-3 fatty acids
Omega-3 fatty acids may have anti-inflammatory effects, although clinical studies show that possible effects have been inconsistent, requiring further research.[17] A 2017 review indicated that omega-3 fatty acids may benefit rheumatoid arthritis,[18] although another analysis indicated no consistent effect. There is no good evidence that use of omega-3 fatty acids provides relief in retinal inflammation or in dry eye syndrome.
N-Acetylcysteine
N-Acetylcysteine (NAC) has been found to possess anti-inflammatory effects and has been clinically studied in the treatment of conditions involving inflammation.[19]
Melatonin
A 2021 review reported that melatonin has anti-inflammatory effects.[20] Found to reduce levels of several pro-inflammatory cytokines, it remains under preliminary research for its potential to treat inflammation.
Serotonin 5-HT2A receptor agonists
Serotonin 5-HT2A receptor agonists, including serotonergic psychedelics, are under preliminary research as possible anti-inflammatory agents.[21] [22] The anti-inflammatory effects of some psychedelics, like DOI and psilocybin, have been found to occur at much lower doses than those at which they produce their hallucinogenic effects. Serotonin 5-HT2A receptor agonists with anti-inflammatory properties are under clinical investigation as possible treatments for inflammatory disorders.[23]
Tetracyclic antibiotics
The tetracycline antibiotics minocycline and doxycycline have been found to have anti-inflammatory and immunomodulatory effects.[24] [25] Minocycline has been found to have some clinical benefit in people with treatment-resistant depression with inflammation but not in those without inflammation.[26]
Macrolide antibiotics
The macrolide antibiotic azithromycin is known to have anti-inflammatory and immunomodulatory properties.[27] It is said to be established and effective for certain inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease (COPD).[28] [29] [30] Azithromycin is also being assessed for potential treatment of other chronic inflammatory disorders.[31] [32]
Statins
Statins like atorvastatin and simvastatin are used to treat inflammatory conditions like rheumatoid arthritis and chronic kidney disease.[33] [34] [35] Statins may be useful for treating other inflammatory conditions, like uveitis, depression,[36] [37] and possibly neuropsychiatric disorders.[38] [39] However, higher-quality evidence of statins for treatment of neuropsychiatric and other conditions is still needed.[40]
Curcumin
A 2019 systematic review and meta-analysis found that curcumin or turmeric did not significantly decrease several circulating inflammatory markers in people with various chronic inflammatory diseases.[41] Major problems of assessing curcumin in human studies are its unknown fate and properties after digestion, and its poor bioavailability.[42] [43] [44]
Notes and References
- Vella-Brincat . Jane . Macleod . A. D. . 2007 . Adverse effects of opioids on the central nervous systems of palliative care patients . Journal of Pain & Palliative Care Pharmacotherapy . 21 . 1 . 15–25 . 1536-0539 . 17430825.
- Book: Ghlichloo I, Gerriets V . Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) . StatPearls [Internet] . Treasure Island (FL) . 1 May 2023 . https://www.ncbi.nlm.nih.gov/books/NBK547742/ . StatPearls Publishing . 31613522 . US National Library of Medicine . 25 May 2025 .
- Knights KM, Mangoni AA, Miners JO . Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity . Expert Review of Clinical Pharmacology . 3 . 6 . 769–776 . November 2010 . 22111779 . 10.1586/ecp.10.120 . 207209534 .
- Web site: Qureshi O, Dua A . COX inhibitors . 28 February 2024 . StatPearls, US National Library of Medicine . 25 May 2025 .
- Web site: Gerriets V, Anderson J, Patel P, Nappe TM . Acetaminophen . 11 January 2024 . 29493991 . StatPearls, US National Library of Medicine . 25 May 2025 .
- Web site: Table 7 . NSAIDs and adverse effects . Bandolier . December 20, 2012 . https://web.archive.org/web/20120218152243/http://www.medicine.ox.ac.uk/bandolier/booth/painpag/nsae/nsae.html#Heading20 . February 18, 2012 .
- Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P . Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis . BMJ . 342 . c7086 . January 2011 . 21224324 . 3019238 . 10.1136/bmj.c7086 .
- Ingawale DK, Mandlik SK . New insights into the novel anti-inflammatory mode of action of glucocorticoids . Immunopharmacology and Immunotoxicology . 42 . 2 . 59–73 . April 2020 . 32070175 . 10.1080/08923973.2020.1728765 .
- Escoter-Torres L, Caratti G, Mechtidou A, Tuckermann J, Uhlenhaut NH, Vettorazzi S . Fighting the Fire: Mechanisms of Inflammatory Gene Regulation by the Glucocorticoid Receptor . Frontiers in Immunology . 10 . 1859 . 2019 . 31440248 . 6693390 . 10.3389/fimmu.2019.01859 . free .
- Scott JP, Peters-Golden M . Antileukotriene agents for the treatment of lung disease . American Journal of Respiratory and Critical Care Medicine . 188 . 5 . 538–544 . September 2013 . 23822826 . 10.1164/rccm.201301-0023PP .
- Niwas H, Bansal P, Pentela B, Mazumder A . The Spectrum of Allergic Rhinitis: Risk Factors and their Clinical Relevance . Recent Advances in Inflammation & Allergy Drug Discovery . October 2025 . 19 . 41126418 . 10.2174/0127722708397912251001102439 .
- Lai Y, Dong C . Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases . International Immunology . 28 . 4 . 181–188 . April 2016 . 26545932 . 4889878 . 10.1093/intimm/dxv063 .
- Li P, Zheng Y, Chen X . Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics . Frontiers in Pharmacology . 8 . 460 . 2017 . 28785220 . 5506195 . 10.3389/fphar.2017.00460 . free .
- Yoo SM, Chung SH . Targets of monoclonal antibodies for immunological diseases . Archives of Pharmacal Research . 42 . 4 . 293–304 . April 2019 . 30426387 . 10.1007/s12272-018-1087-2 .
- Book: Shekelle PG, FitzGerald J, Newberry SJ, Motala A, O'Hanlon CE, Okunogbe A, Tariq A, Han D, Dudley W . Methods . Management of Gout [Internet] . March 2016 . https://www.ncbi.nlm.nih.gov/books/NBK356142/ . 2025-11-04 . Agency for Healthcare Research and Quality (US) . en .
- Book: Clinical Review . Colchicine (Myinfla): CADTH Reimbursement Review: Therapeutic area: Atherothrombotic events in coronary artery disease [Internet] . April 2022 . https://www.ncbi.nlm.nih.gov/books/NBK599003/ . 2025-11-04 . Canadian Agency for Drugs and Technologies in Health . en .
- Web site: Omega-3 Fatty Acids: Fact Sheet for Health Professionals . 17 December 2024 . Office of Dietary Supplements, US National Institutes of Health . 25 May 2025 .
- Calder PC . Omega-3 fatty acids and inflammatory processes: from molecules to man . Biochemical Society Transactions . 45 . 5 . 1105–1115 . October 2017 . 28900017 . 10.1042/BST20160474 .
- Santus P, Signorello JC, Danzo F, Lazzaroni G, Saad M, Radovanovic D . Anti-Inflammatory and Anti-Oxidant Properties of N-Acetylcysteine: A Fresh Perspective . Journal of Clinical Medicine . 13 . 14 . July 2024 . 39064168 . 11278452 . 10.3390/jcm13144127 . 4127 . free .
- Cho JH, Bhutani S, Kim CH, Irwin MR . Anti-inflammatory effects of melatonin: A systematic review and meta-analysis of clinical trials . Brain, Behavior, and Immunity . 93 . 245–253 . March 2021 . 33581247 . 7979486 . 10.1016/j.bbi.2021.01.034 .
- Nichols DE, Johnson MW, Nichols CD . Psychedelics as Medicines: An Emerging New Paradigm . Clinical Pharmacology and Therapeutics . 101 . 2 . 209–219 . February 2017 . 28019026 . 10.1002/cpt.557 .
- Nichols CD . Psychedelics as potent anti-inflammatory therapeutics . Neuropharmacology . 219 . 109232 . November 2022 . 36007854 . 10.1016/j.neuropharm.2022.109232 . free .
- Kozlowska U, Nichols C, Wiatr K, Figiel M . From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders . Journal of Neurochemistry . 162 . 1 . 89–108 . July 2022 . 34519052 . 10.1111/jnc.15509 .
- Park CS, Kim SH, Lee CK . Immunotherapy of Autoimmune Diseases with Nonantibiotic Properties of Tetracyclines . Immune Network . 20 . 6 . e47 . December 2020 . 33425432 . 7779869 . 10.4110/in.2020.20.e47 .
- Singh S, Khanna D, Kalra S . Minocycline and Doxycycline: More Than Antibiotics . Current Molecular Pharmacology . 14 . 6 . 1046–1065 . 2021 . 33568043 . 10.2174/1874467214666210210122628 .
- Al Jumaili W, Vora D, Trivedi C, Jain S . Role of Minocycline as an Adjunct Neuroinflammatory Modulator in Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials . The Primary Care Companion for CNS Disorders . 25 . 5 . September 2023 . 37713730 . 10.4088/PCC.22r03467 . Results: Minocycline as an adjunct immunomodulator shows inconsistent benefit in TRD. Minocycline has some beneficial effect on depression scale scores and inflammatory markers in TRD patients with inflammatory disequilibrium (C-reactive protein elevation exceeds 3 mg/L). However, minocycline showed an inconclusive effect in TRD with no clear immunologic dysregulation. .
- Firth A, Prathapan P . Azithromycin: The First Broad-spectrum Therapeutic . European Journal of Medicinal Chemistry . 207 . 112739 . December 2020 . 32871342 . 7434625 . 10.1016/j.ejmech.2020.112739 .
- Pollock J, Chalmers JD . The immunomodulatory effects of macrolide antibiotics in respiratory disease . Pulmonary Pharmacology & Therapeutics . 71 . 102095 . December 2021 . 34740749 . 8563091 . 10.1016/j.pupt.2021.102095 .
- Hiles SA, McDonald VM, Guilhermino M, Brusselle GG, Gibson PG . Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis . The European Respiratory Journal . 54 . 5 . November 2019 . 31515407 . 10.1183/13993003.01381-2019 . free . 1765/122222 .
- Mackay AJ, Hurst JR . COPD exacerbations: causes, prevention, and treatment . The Medical Clinics of North America . 96 . 4 . 789–809 . July 2012 . 22793945 . 10.1016/j.mcna.2012.02.008 .
- Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R . Azithromycin: mechanisms of action and their relevance for clinical applications . Pharmacology & Therapeutics . 143 . 2 . 225–245 . August 2014 . 24631273 . 10.1016/j.pharmthera.2014.03.003 .
- Hirsch R, Deng H, Laohachai MN . Azithromycin in periodontal treatment: more than an antibiotic . Journal of Periodontal Research . 47 . 2 . 137–148 . April 2012 . 22050485 . 10.1111/j.1600-0765.2011.01418.x .
- Li GM, Zhao J, Li B, Zhang XF, Ma JX, Ma XL, Liu J . The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials . Autoimmunity Reviews . 17 . 3 . 215–225 . March 2018 . 29353098 . 10.1016/j.autrev.2017.10.013 .
- Wang J, Chen Z, Qiu Y, Wu L, Wang H, Wu L, Zhao L, Xie D . Statins Have an Anti-Inflammation in CKD Patients: A Meta-Analysis of Randomized Trials . BioMed Research International . 2022 . 4842699 . 2022 . 36317110 . 9617709 . 10.1155/2022/4842699 . free .
- Gilbert R, Al-Janabi A, Tomkins-Netzer O, Lightman S . Statins as anti-inflammatory agents: A potential therapeutic role in sight-threatening non-infectious uveitis . Porto Biomedical Journal . 2 . 2 . 33–39 . 2017 . 32258583 . 6806973 . 10.1016/j.pbj.2017.01.006 . In addition to the known lipid-lowering effects, statins are now widely accepted to have anti-inflammatory and immunomodulatory effects. Adjunctive use of statins has proven beneficial in the context of a wide range of inflammatory diseases, including rheumatoid arthritis. .
- De Giorgi R, De Crescenzo F, Rizzo Pesci N, Martens M, Howard W, Cowen PJ, Harmer CJ . Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials . PLOS ONE . 16 . 3 . e0249409 . 2021 . 33784356 . 8009386 . 10.1371/journal.pone.0249409 . 2021PLoSO..1649409D . free .
- Bai S, Guo W, Feng Y, Deng H, Li G, Nie H, Guo G, Yu H, Ma Y, Wang J, Chen S, Jing J, Yang J, Tang Y, Tang Z . Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials . Journal of Neurology, Neurosurgery, and Psychiatry . 91 . 1 . 21–32 . January 2020 . 31658959 . 10.1136/jnnp-2019-320912 .
- Avan R, Sahebnasagh A, Hashemi J, Monajati M, Faramarzi F, Henney NC, Montecucco F, Jamialahmadi T, Sahebkar A . Update on Statin Treatment in Patients with Neuropsychiatric Disorders . Life . 11 . 12 . December 2021 . 34947895 . 8703562 . 10.3390/life11121365 . 1365 . free . 2021Life...11.1365A .
- Fitton R, Sweetman J, Heseltine-Carp W, van der Feltz-Cornelis C . Anti-inflammatory medications for the treatment of mental disorders: A scoping review . Brain, Behavior, & Immunity - Health . 26 . 100518 . December 2022 . 36217374 . 9547233 . 10.1016/j.bbih.2022.100518 .
- Köhler-Forsberg O, Otte C, Gold SM, Østergaard SD . Statins in the treatment of depression: Hype or hope? . Pharmacology & Therapeutics . 215 . 107625 . November 2020 . 32652185 . 10.1016/j.pharmthera.2020.107625 .
- White CM, Pasupuleti V, Roman YM, Li Y, Hernandez AV . Oral turmeric/curcumin effects on inflammatory markers in chronic inflammatory diseases: A systematic review and meta-analysis of randomized controlled trials . Pharmacological Research . 146 . 104280 . August 2019 . 31121255 . 10.1016/j.phrs.2019.104280 .
- Liu W, Zhai Y, Heng X, Che FY, Chen W, Sun D, Zhai G . Oral bioavailability of curcumin: problems and advancements . Journal of Drug Targeting . 24 . 8 . 694–702 . September 2016 . 26942997 . 10.3109/1061186X.2016.1157883 .
- Hegde M, Girisa S, BharathwajChetty B, Vishwa R, Kunnumakkara AB . Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far? . ACS Omega . 8 . 12 . 10713–10746 . March 2023 . 37008131 . 10061533 . 10.1021/acsomega.2c07326 . free.
- Khosravi MA, Seifert R . Clinical trials on curcumin in relation to its bioavailability and effect on malignant diseases: critical analysis . Naunyn-Schmiedeberg's Archives of Pharmacology . 397 . 5 . 3477–3491 . May 2024 . 37966571 . 11074217 . 10.1007/s00210-023-02825-7 .